

## Erratum to: Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma

Shinsuke Iida · Takaaki Chou · Shinichiro Okamoto · Hirokazu Nagai · Kiyohiko Hatake · Hirokazu Murakami · Toshiyuki Takagi · Kazuyuki Shimizu · Henry Lau · Kenichi Takeshita · Masaaki Takatoku · Tomomitsu Hotta

Published online: 1 July 2010  
© The Japanese Society of Hematology 2010

**Erratum to: Int J Hematol**  
**DOI 10.1007/s12185-010-0624-7**

There are errors in Table 2. The numbers and the percentages for grades 3 and 4 adverse events are incorrectly aligned. The correct version of the table appears on the following page.

---

The online version of the original article can be found under doi:[10.1007/s12185-010-0624-7](https://doi.org/10.1007/s12185-010-0624-7).

---

S. Iida (✉)  
Department of Medical Oncology and Immunology,  
Nagoya City University Graduate School of Medical Sciences,  
1, Kawasumi, Mizuho-cho, Mizuho-ku,  
Nagoya 467-8601, Japan  
e-mail: [iida@med.nagoya-cu.ac.jp](mailto:iida@med.nagoya-cu.ac.jp)

T. Chou  
Department of Internal Medicine,  
Niigata Cancer Center Hospital, Niigata, Japan

S. Okamoto  
Division of Hematology,  
Keio University School of Medicine,  
Tokyo, Japan

H. Nagai · T. Hotta  
National Hospital Organization Nagoya Medical Center,  
Nagoya, Japan

K. Hatake  
Cancer Institute Hospital, Tokyo, Japan

H. Murakami  
School of Health Sciences, Faculty of Medicine,  
Gunma University, Maebashi, Japan

T. Takagi  
Kimitsu Chuo Hospital, Kisarazu, Japan

K. Shimizu  
Nagoya City Midori General Hospital, Nagoya, Japan

H. Lau · K. Takeshita  
Celgene Corporation, Summit, USA

K. Takeshita · M. Takatoku  
Celgene KK, Tokyo, Japan

**Table 2** Lenalidomide-related adverse events with NCI-CTCAE grade 3 or 4 ( $n = 15$ )

A subject with multiple occurrence of an adverse event is counted once

<sup>a</sup> In 3 cases of lymphopenia, one was reported as a lenalidomide and/or dexamethasone-related AE

<sup>b</sup> Lenalidomide and/or dexamethasone-related AEs

Events	Grade 3	Grade 4	Grade 3 + 4, $n$ (%)
Patients with at least one $\leq$ grade 3 adverse event			11 (73.3)
Anemia	–	2 (13.3)	2 (13.3)
Leukopenia	3 (20.0)	–	3 (20.0)
Lymphopenia	3 (20.0) <sup>a</sup>	–	3 (20.0)
Neutropenia	9 (60.0)	1 (6.7)	10 (66.7)
Hypoxia	1 (6.7)	–	1 (6.7)
Malaise <sup>b</sup>	1 (6.7)	–	1 (6.7)
Hepatic function abnormality <sup>b</sup>	1 (6.7)	–	1 (6.7)
Decreased blood phosphorus	1 (6.7)	–	1 (6.7)
Increased alanine aminotransferase <sup>b</sup>	1 (6.7)	–	1 (6.7)